期刊文献+

血清TIMP-1测定在肝炎、肝硬化中的诊断价值

Diagnostic Value of Determination of Serum Tissue Inhibitor of Matrix Metallo-Proteinase-1 (TIMP-1) Levels in Patients with Hepatitis and Cirrhosis
下载PDF
导出
摘要 目的:了解肝炎、肝硬化患者基质金属蛋白酶抑制因子(TIMP-1)在血清中的表达以及肝纤维化的情况,探讨肝炎致肝硬化的机理。方法:用ELISA检测TIMP-1在肝炎、肝硬化患者血清中的含量,同时检测HA、PCⅢ、CⅣ、LN。结果:肝硬化患者血清中TIMP-1的含量与肝炎组相比显著增加,TIMP-1与HA、PCⅢ、CⅣ、LN呈明显正相关。结论:TIMP-1在血清中的含量可判断肝脏纤维化的程度,为肝硬化的诊断提供实验依据。 Objective To investigate thd relationship between the degree of hepatic fibrosis and serum expression of tissue inhibi- tor of matrix metalloproteinase - 1 ( TIMP - 1 ) in Patients with hepatitis and cirrhosis. Methods Serum TIMP - 1 ( with ELISA) and hepatic fibrosis markers HA, PC Ⅲ, C Ⅳ, LN ( with KIA) contents were measured in 33 patients with hepatic cirrhosis and 30 patients with viral hepatitis. Results The serum levels of TIMP - 1 in patients with hepatic cirrhosis were significantly higher than those in patients with hepatitis. Levels of TIMP - 1 were significantly positively correlated with levels of the hepatic fibrosis markers HA, PC Ⅲ, CⅣ and LN. Conclusion TIMP - 1 could be used as a marker of hepatic fibrosis and could be helpful for diagnosis of cirrhosis.
出处 《放射免疫学杂志》 CAS 2007年第6期574-575,共2页 Journal of Radioimmanology
关键词 基质金属蛋白酶抑制因子 肝硬化 肝纤维化 tissue inhibitor of matrix metalloproteinase - 1, cirrhosis, hepatic fibrosis
  • 相关文献

参考文献8

二级参考文献22

  • 1[1]Mark DS, Werb Z. ECM proteinases [A]. Thomas K,Ronal V. Guidebook to the extracellular matrix, anchor, and anhesion proteins [M]. ed 2. New York: Oxford University Press Inc, 1999.505-509.
  • 2[2]Sternlicht MD, Coussens LM, Vu TH, et al. Biology and regulation of the matrix metalloproteinases [A]. Clendeninn NJ, Appelt K. Matrix metalloproteinase inhibitors in cancer therapy [M]. Totowa: Humana Press Inc, 2001.1-37.
  • 3[3]Cox G, O'byrne KJ. Matrix metalloproteinase and cencer [J]. Anticancer Res, 2001,21(6B):4207-4219.
  • 4[4]O-charoenrat P, Modjtahedi H, Rhys-Evans P. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells [J]. Cancer Res, 2000,60(4):1121-1128.
  • 5[5]Cox G, Jones JL,O'Byrne KJ. MMP-9 and the epidermal growth factor receptor signal pathway in operable non-small cell lung cancer [J]. Clin Cancer Res, 2000,6(6):2349-2355.
  • 6[6]Westermarck J,Kahari VM.Regulation of matrix met-salloproteinase expression in tumor invasion [J]. FASEB J, 1999,13(8):781-792.
  • 7[7]Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage [J]. Curr Opin Cell Biol, 1999,11(2):219-225.
  • 8[8]Reddy KB, Kreuger JS, Kondapaka SB, et al. Mitogenactivated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells [J]. Int J Cancer, 1999,82(2):268-273.
  • 9[9]lizasa T, Fujisawa T, Suzuki M. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients [J]. Clin Cancer Res,1999,5(1):149-153.
  • 10[10]Fleming MV, Colby TV, Bennett W. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions [J]. Hum Pathol,2000,31(3):296-305.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部